In the clinical trial, NCT04429542 is a phase I/Ib study evaluating the safety, tolerability, and preliminary efficacy of the novel therapeutic agent BCA101, which targets both EGFR and TGF-β, in patients with recurrence/metastatic HNSCC. The gene discussed is TGFB1; the disease is head and neck squamous cell carcinoma.